High -risk HPV infection is the main cause of cervical cancer. Vaccination is the most effective first -level prevention measure

Cervical cancer, as one of the common gynecological malignant tumors, shows the characteristics of high departure rate and high mortality, while high -risk HPV (human papilloma virus) infection is its main cause.

Studies have confirmed that vaccination HPV vaccine is the most effective first -level prevention measure for cervical cancer. Sui Long, director of the Cervical Disease Diagnosis and Treatment Center of the Obstetrics and Gynecology Hospital affiliated to Fudan University, said that there have been more than 200 types of HPVs. According to different carcinogenicity, it is divided into high -risk types and low -risk types. A epidemic study that summarizes 1.7 million women's HPV infections in China shows that the HPV high -risk types that women in China are most vulnerable to women in China are HPV16, 52, and 58, respectively.

"HPV is mainly infected through sexual contact. There are more than 600,000 cases that cause new cervical cancer every year in the world." According to Sui Long, after the infection of HPV, in the extension of time, the infected cells will change, from tumor changes to causing cause Cervical cancer lesions develop cervical cancer until a small number of women develop. In addition to cervical cancer, high -risk HPVs can also cause cancer in anus, vulva, head and neck, and related diseases such as condyloma acuminatum. HPV vaccines can prevent diseases, including malignant tumors infected by HPV infections, can be prevented, making cervical cancer hope to be the earliest and first eliminated human malignant tumors.

There are currently available HPV vaccines in China. Sui Long said that the binary HPV vaccine covers HPV16 and 18; the quadrimal HPV vaccine covers HPV16, 18, 6, and 11; For girls' pre -reproductive tract cancer lesions, especially five other high -risk types of cervical cancer, namely HPV31, 33, 45, 52, 58.

It is reported that the nine-valent HPV vaccine has been approved by the State Drug Administration a few days ago, and the applicable population has expanded to women 9-45 years old. In this regard, Sui Long said that HPV infection presented two "peaks" in China: the first peak infection appeared at 17-24 years old, and the second peak was 40-44 years old. The applicable age of the nine-valent HPV vaccine has expanded from the original 16-26 years to 9-45 years.

Sui Long explained that the risk of adult women's infection HPV is much larger than women before sex. At the same time, as the age increases, the risk of immunity will increase after infection with HPV. A large number of real world studies at home and abroad have proven that adult women's inoculation HPV vaccines are very necessary, and they also have a good protective effect.

Regarding the safety of the HPV vaccine, Sui Long said that the HPV vaccine does not contain the pathogenic genetic material of the virus and has experienced long -term and extensive verification of safety monitoring after listing and after listing. Or complications, you can rest assured.

Sui Long emphasized that cervical cancer prevention and control is a three -level prevention system. HPV vaccines are the main first -level prevention measures. At present, the coverage rate of inoculation of women in appropriate age in my country is far from enough. A survey among college students in some cities shows that the coverage of HPV vaccines is less than 3%, and we have a long way to go. On the one hand, the government must formulate a corresponding and feasible policy of promoting HPV vaccine coverage according to local conditions; on the other hand, enterprises should increase supply and improve vaccine can be available.

In recent years, my country has paid great attention and support for the popularization of HPV vaccine and the first prevention of cervical cancer. Under the vision of China's "eliminating cervical cancer" goal, provinces and cities have accelerated the layout of HPV vaccines into the local immunization plan, enhanced the vaccination rate of key groups, explored more flexible vaccination funds and vaccination policies, and found the characteristics suitable for my country's characteristics to eliminate cervix to eliminate cervix. The best path for cancer targets. With the continuous increase in the supply of Nine -valent HPV vaccine, the continuous improvement of accessibility and vaccination rates will continue to improve the health and well -being of women and promote my country's pace of eliminating the elimination of cervical cancer. (Guangming Daily All Media Reporter Tian Yating)

Suai Long

- END -